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Abstract Cerebral arterioveneous malformations (AVM)
can cause neurological symptoms and carry a risk of
hemorrhage. Therapeutic options to cure or reduce AVM
include surgery, embolization, irradiation, and combina-
tions thereof. Prompted by three index cases treated in our
center, we studied whether AVM embolization is associ-
ated with an increased risk of subsequent amyotrophic
lateral sclerosis (ALS). In a monocenter series, we retro-
spectively analyzed the new development of ALS in
patients who had been treated with embolization of cere-
bral AVM from 1986 to 2010 (n = 1,114). After a median
follow-up of 11 years (range, 0–25 years) after first
embolization, seven patients developed ALS with a median
latency of 14 years (range, 12–17 years) and a median age
of ALS onset of 38 years (range, 28–52 years). In all cases,
the initial limb of ALS symptom onset was ipsilateral to the
AVM. Five patients died within the follow-up period, with
a range of 1–4 years after the onset of ALS symptoms. The
seven patients belonged to a subgroup of 34 patients who
had in common a rare AVM architecture characterized by
significant perinidal angiogenesis. All cases were partially
treated by at least three embolization sessions. As there is
no known association between AVM and ALS, AVM
embolization must be taken into account to have contrib-
uted to the development of ALS in the seven patients with
this rare AVM architecture. Searching for underlying
mechanisms, we compared frozen serum samples that were
available from four of the patients who developed ALS,
from eight patients with AVM of other architecture, and
less than three embolizations who did not develop ALS,
and of 20 controls. The concentration of vascular endo-
thelial growth factor (VEGF) in the serum was lowest in
AVM patients who developed ALS (245 ± 154 pmol/l)
and highest in controls (409 ± 178 pmol/l). Although this
difference was not statistically significant in the small
sample, it suggests that low VEGF production by AVM
with significant angiogenesis, possibly due to multiple
embolization procedures, might have contributed to ALS
development. ALS should be considered as a late compli-
cation of multiple embolizations of cerebral AVM char-
acterized by significant perinidal angiogenesis.
Keywords AVM  ALS  Embolization  Amyotrophic
lateral sclerosis  Arterioveneous malformation
Introduction
Cerebral arterioveneous malformations (AVM) are char-
acterized by multiple shunts between feeding arteries and
draining veins via a nidus, without interposition of a cap-
illary bed. Brain AVM are detected in approximately 1.1/
100,000 person-years and carry a life-long risk of hemor-
rhage of approximately 2–4 % per year [3, 4]. Further
symptoms include headache, seizures, and focal neuro-
logical deficits. While the majority of AVM do not induce
perilesional angiogenesis (=AVM proper), a small
proportion of AVM induce hypoxia in the surrounding
brain parenchyma, leading to perinidal angiogenesis
(Fig. 1) [1, 2].
Treatment of AVM includes microsurgical resection,
embolization, stereotactic radiosurgery, or combinations
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thereof. Embolization is used to reduce nidal size prior to
surgical resection or radiosurgery, to selectively eliminate
areas at high risk of hemorrhage, or to completely oblit-
erate the nidus. Cyanoacrylate, polyvinyl alcohol micro-
particles and, more recently, ethylene vinyl alcohol
copolymers are frequently used agents for embolization
[5]. The known long-term complications of embolization of
cerebral AVM include hemorrhage, edema, and ischemia.
Methods
Within 1 year, we prospectively diagnosed new-onset ALS
in three patients who had been treated with embolization of
brain AVM several years before. To retrospectively search
for further cases of ALS after AVM embolization, we
systematically reviewed our electronic patient records of
all patients treated with embolization for AVM at the
Institute of Neuroradiology between 1986 and 2010.
Arterioveneous malformations size and shape, the
diameter of the nidus, dural supply, and proportion of
AVM occlusion were defined as earlier described in detail
[2].
Diagnosis of definite or probable ALS followed the
modified Airlie House El Escorial criteria [6]. Vascular
endothelial growth factor (VEGF) concentrations were
measured in serum and cerebrospinal fluid (CSF) by
enzyme-linked immunosorbent assay (ELISA; R&D Sys-
tems, Abingdon, UK). Twenty CSF samples of patients
with acute headache punctured for the exclusion of men-
ingitis or subarachnoid bleeding, but without CSF abnor-
malities or AVM served as controls.
ANOVA, Pearson’s v2 tests, and Pearson’s correlation
were calculated with SPSS version 16 (SPSS, Somers, NY,
USA). This retrospective analysis of data derived from
patients treated by the authors did not require written
consent of the patients or an ethics committee vote: http://
www.kek.zh.ch/internet/gesundheitsdirektion/kek/de/vorge
hen_gesuchseinreichung.html#subtitle-content-internet-
gesundheitsdirektion-kek-de-vorgehen_gesuchseinreichung-
jcr-content-contentPar-textimage_3.
Results
Population
At the Institute of Neuroradiology, University Hospital
Zurich, 1,114 patients with brain AVM were treated with
embolization from 1986 until the end of 2010. The total
sample had a median follow-up of 11 years (range,
0–25 years).
ALS cases
Including the three index cases, seven out of the 1,114
patients had been diagnosed with definite ALS according to
the electronic patient records (1:159; exact 95 % confi-
dence interval 1:395–1:78; Table 1; Fig. 2). All diagnoses
had been made at our institution. No further patients were
diagnosed with probable ALS. In two additional patients
who developed tetraparesis, ALS could not be ruled out,
but was considered not likely: one was diagnosed with
tetraparesis due to encephalitis, and the other had venous
congestion caused by the AVM. Both were lost to follow-
up and were not included in further analyses. Further, nine
deaths due to spontaneous intracerebral hemorrhage sup-
posedly related to the AVM were documented.
Of the seven patients with definite ALS appearing after
AVM embolization, three were female and four were male
(Table 1). For the ALS cases, a detailed family history had
been documented. None of the patients’ parents or siblings
had ALS or other neurodegenerative diseases. Median age
of onset of ALS was 38 years (range, 28–52 years). In
three of the seven patients, AVM embolization was per-
formed because they had refused any other type of AVM
treatment. In the other four patients, AVM was classified as
inoperable, and AVM size was beyond the range of irra-
diation therapy. Location, size, and first symptoms of the
AVM as well as the embolization agent were heteroge-
neous (Table 1). Three of the seven patients presented with
AVM-related hemorrhage as the first symptom. However,
Fig. 1 DSA of AVM Lateral digital subtraction angiography (DSA)
in patient ID = 4 before embolization showing a large AVM (thick
arrow) in the left superior frontal gyrus associated with marked
perinidal angiogenesis (asterisks) and additional dural supply via the
middle meningeal artery (arrowhead)
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the seven patients also shared several attributes: All AVMs
were characterized by neopallial location, marked addi-
tional dural supply, and significant perinidal angiogenesis
(Fig. 1). In addition, all patients underwent at least three
embolization sessions (median 4; range, 3–6). No AVMs
were completely obliterated (approximately 40–90 % as
estimated by angiography; Fig. 3). No patient developed
sustained ischemic or hemorrhagic damage due to the
embolization procedure itself as analyzed clinically and by
follow-up MRI. The seven patients developed the first ALS
symptoms after a median latency of 14 years (range,
12–17 years) from the first embolization. In all cases, the
initial limb of ALS symptom onset was ipsilateral to the
AVM, before deficits spread to the other body site within
weeks or months and progressed in a rather symmetrical
spinal distribution type. In addition, one patient presented
with additional bulbar symptoms (Table 1). MRI did not
show an affection of the motor segment of the corpus
callosum. Three of the seven had MRI abnormalities in
motor cortex consistent with ALS findings. The later
clinical course did not differ from patients with sporadic
ALS. All patients had signs of both upper and lower motor
neuron degeneration confirmed in standardized electro-
physiological analyses. Five patients had died by the end
of 2010, with a range of 1–4 years after the onset of ALS
symptoms. Necropsies were not obtained.
Analysis of the entire 1,114 AVM patients treated with
embolization revealed that those seven who developed
ALS belonged to a small subgroup of 34 patients (1:4.9,
exact 95 % confidence intervals 1:11.5–1:2.64) character-
ized by AVM with significant perinidal angiogenesis,
incomplete embolizations, and multiple (at least three)
embolization sessions (Fig. 3). Whereas 7,606 emboliza-
tion procedures were performed in our hospital in 5,754
patients with diagnoses including hyper-vascularized
tumors, arteriovenous malformations, and intradural
aneurysms in the time period of 1986–2010, no further
diagnoses of ALS or symptoms suspicious for ALS were
documented in our database.
VEGF
In the CSF laboratory, residual CSF and serum samples are
routinely stored as a backup at -80 C after analyses.
Such samples were available from four patients who had
developed ALS after AVM embolization. These samples
had been ascertained during the diagnostic work-up of the
first ALS symptoms, i.e., after the last of 3–5 emboliza-
tions (Table 1). Eight residual samples were available from
other AVM patients, i.e., who had AVM without perinidal
angiogenesis and did not develop ALS. Those patients had
had lumbar punctures for the exclusion of subarachnoid
hemorrhage at first presentation or up to 15 years after 0–2T
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embolizations. Although samples from AVM patients were
not collected in a standardized manner and the number was
too small for valid statistical analysis, we analyzed VEGF
in these samples, as they are the only source for any
information on the possible association of VEGF with ALS
development in AVM patients. The concentrations of
VEGF in the CSF samples were below the lower limit of
accurate detection (15 pg/ml). The concentrations of
VEGF in the serum were numerically lowest in AVM
patients who developed ALS (245 ± 154 pmol/l) and
highest in controls (409 ± 178 pmol/l), but in this small
group, those differences were not statistically significant
(Table 2).
Discussion
Amyotrophic lateral sclerosis is a sporadic or occasionally
genetic disease with an annual incidence rate of approxi-
mately 2.5 per 100,000 characterized by progressive
degeneration of upper and lower motor neurons in the
motor cortex, brainstem, and spinal cord leading to pro-
gressive limb weakness, bulbar palsy, and respiratory
insufficiency [7]. No effective therapy exists. The median
survival time from ALS onset to death, mostly from
respiratory failure, ranges from 20 to 48 months [8].
The patients reported here developed ALS symptoms
12–17 years after the first session of embolization treatment
of cerebral AVM. The appearance of ALS in seven cases out
of a population of 1,114 patients or, more precisely, out of a
subgroup of 34 patients harboring the same AVM subtype
cannot be explained by chance alone. Further, the median
age at onset of 38 years was much lower than in sporadic
ALS (approximately 65 years) [8]. Various hypotheses to
explain this observation may be considered:
AVM and ALS could be genetically
or pathophysiologically linked
However, no linkage of ALS to genes that may be involved
in generating predispositions to AVM has been identified.
The family history of the seven patients was free from ALS
and AVM, and a clinical association of ALS with AVM has
not been reported.
The agents used for embolization may induce motor
neuron degeneration
Used as embolic agents in mammals, cyanoacrylate and
polyvinyl alcohol have been reported to induce chronic
Fig. 2 AVM and signs of ALS
in MRI. a Axial T2-weighted
MRI showing the AVM in the
left frontal gyrus. At this stage,
the patient (ID = 4; Table 1)
had no symptoms of motor
neuron disease. b Four years
later, when the patient
developed symptoms suggestive
of ALS, MRI shows decreased
size of the AVM after partial
embolization. There are
abnormal low signal intensities
in the right motor cortex
compatible with ALS (arrow)
Brain AVM (n=1114; total number of embolisation sessions: 2201; ALS: n=7)
AVM proper 
(n=858)
AVM with perinidal angiogenesis
(n=256)
complete embolisation 
(n=67)
partial embolisation 
(n=189)
1-2 embolisations 
(n=155)
≥3 embolisations 
(n=34)
no ALS 
(n=27)
ALS
(n=7)
Fig. 3 Characteristics of all AVM patients treated with emboliza-
tions in Zurich (1986–2010). In the group of 34 patients with AVM
with perinidal angiogenesis, partial embolizations, and C3 emboliza-
tions, seven patients developed ALS. In the other groups, no diagnosis
or symptoms equivocal for ALS were documented in the electronic
patient records
J Neurol (2014) 261:732–737 735
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inflammation in vessel walls and adjacent brain paren-
chyma characterized by an infiltration with leukocytes and
giant cell reactions [9–12]. In chronic inflammatory CNS
diseases like multiple sclerosis, inflammation may precede
clinical symptoms by many years, and neuroinflammation
is observed in the CNS from both human ALS patients and
mouse models of the disease [13]. Thus, the embolic agents
might have initiated a cascade of CNS inflammation
yielding degeneration of upper and lower motor neurons
via an as-yet-unknown mechanism. However, in all our
cases, the initial ALS manifestation was on the body’s
ipsilateral side of the AVM, i.e., resulting from impairment
of the hemisphere contralateral to the embolized AVM,
which makes a direct toxic effect of the embolization agent
on the surrounding brain parenchyma as cause of neuronal
degeneration improbable. Moreover, the lower motor
neurons were in large physical distance to the location were
the embolic agents were applied, but were nevertheless
affected together with the upper motor neurons.
Repetitive incomplete reduction of cerebral AVM
with perinidal angiogenesis by embolization may
induce ALS
VEGF promotes cerebral perfusion and contributes to
motor neuron integrity [14, 15]. After latency, mice with
low systemic VEGF levels develop an ALS-like phenotype
[16–18]. Accordingly, the significant association of the
low-VEGF-2578AA genotype with increased susceptibility
to ALS in males reappraises the link between reduced
VEGF concentrations and ALS [17]. Further, ALS patients
have decreased plasma and CSF levels of VEGF and
cannot up-regulate VEGF as normally observed in the CSF
in response to hypoxemia [19–22].
In patients with cerebral AVM, VEGF synthesis is also
abnormal. VEGF expression in the endothelium, suben-
dothelium, and adventitia of AVM specimens is much
higher than in normal brain [23]. This local VEGF pro-
duction inhibits systemic VEGF production as indicated by
lower VEGF plasma levels in AVM patients compared
with controls [24, 25]. In AVM with perinidal angiogene-
sis, arterioveneous shunts lead to hypoxia in the brain tis-
sue surrounding the AVM. This promotes VEGF
production and VEGF-derived angiogenesis (Fig. 1) [2].
After embolization, local VEGF production decreases as a
consequence of both AVM reduction and improvement of
perfusion. Consequently, systemic VEGF production
increases, but does not compensate for the already-inhib-
ited AVM VEGF production [24]. Accordingly, VEGF
levels in the four available serum samples of our AVM
patients who developed ALS tended to be lower than in
AVM patients who did not develop ALS or in non-AVM
controls (Table 2). In all seven patients who developed
ALS (Fig. 2), multiple incomplete embolizations were
necessary. It remains speculative as to whether multiplicity
of embolizations or of other procedure-related factors like
multiple anesthetics or any characteristics of that specific
AVM that made multiple embolizations necessary are rel-
evant risk factors. We did not find any difference between
the seven patients who developed ALS and the 21 patients
with AVM with similar AVM who did not. It is uncertain
whether longer follow-up will show more patients with
ALS. Necropsies of our patients were not available. Thus,
we can only speculate about reasons of the clinically
obvious onset of pathology contralateral to the AVM.
Residual VEGF production of the AVM might have
delayed ALS pathology in the surrounding of the AVM.
For possible future cases, respective analysis as well as
ALS pathology staging, e.g., by the analysis of the
spreading neuronal inclusions of phosphorylated 43-kDa
TAR DNA-binding protein (pTDP-43) as suggested by
Brettschneider et al. [26], might be valuable.
In summary, in a cohort of 1,114 embolized AVM
patients, seven out of a subgroup of 34 patients who had an
AVM with perinidal angiogenesis and who were treated by
C3 incomplete embolizations developed ALS. We cannot
exclude additional undiagnosed or new ALS cases that
have not yet appeared in any of the AVM patients. ALS
should be considered as a risk of embolization of cerebral
AVM. This risk may be restricted to a well-defined small
subgroup of AVM patients. It may be useful to get genetic
testing in these patients concerning the VEGF genotype
[17]. Whether a limitation of the number of embolization
sessions reduces this risk in respective patients remains to
be shown, but it may be necessary to be cautious with
multiple embolizations in respective future patients.
Table 2 VEGF serum levels in patients and controls
Group Median age (range) Ratio female VEGF serum ± 1 SD
(pmol/l)
ANOVA vs. controls
Embolized AVM and ALS (n = 4) 38 (28–46) 0.50 245 ± 154 F = 2.9; p = 0.105
Embolized AVM, no ALS (n = 8) 45 (25–59) 0.50 310 ± 145 F = 2.1; p = 0.161
Controls
(n = 20)
38 (28–48) 0.50 409 ± 178 _
SD standard deviation, median age (in years): when samples were taken
736 J Neurol (2014) 261:732–737
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